Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Developing lipid nanoparticle-based siRNA therapeutics for hepatocellular carcinoma using an integrated approach.

Li L, Wang R, Wilcox D, Sarthy A, Lin X, Huang X, Tian L, Dande P, Hubbard RD, Hansen TM, Wada C, Zhao X, Kohlbrenner WM, Fesik SW, Shen Y.

Mol Cancer Ther. 2013 Nov;12(11):2308-18. doi: 10.1158/1535-7163.MCT-12-0983-T. Epub 2013 Aug 13.

2.

Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery.

Li L, Wang R, Wilcox D, Zhao X, Song J, Lin X, Kohlbrenner WM, Fesik SW, Shen Y.

Gene Ther. 2012 Jul;19(7):775-80. doi: 10.1038/gt.2011.146. Epub 2011 Sep 29.

3.

A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors.

Lin X, Li L, Wang R, Wilcox D, Zhao X, Song J, Huang X, Hansen TM, Dande P, Wada C, Hubbard RD, Kohlbrenner WM, Fesik SW, Shen Y.

RNA. 2011 Apr;17(4):603-12. doi: 10.1261/rna.2546011. Epub 2011 Feb 14.

4.

3-D structure of a mutant (Asp101-->Ser) of E.coli alkaline phosphatase with higher catalytic activity.

Chen L, Neidhart D, Kohlbrenner WM, Mandecki W, Bell S, Sowadski J, Abad-Zapatero C.

Protein Eng. 1992 Oct;5(7):605-10.

PMID:
1480614

Supplemental Content

Loading ...
Support Center